Agree with you. Wish our regulators are not sleeping
Spi2012 is at least 4 years from reaching market IF all clinical and regulatory risks go well for spectrum.
By then 10s of new cancer drugs will come to MKT and could make spi2012 obsolete
2014 the hype has gone to spi 2012 which is IMHO 4 years away from reaching market if a ton of things go right. And trust me by then there will likely be other competition.
Apaz has failed p3 trial
Sentiment: Strong Sell
In 2012 on fusilev, they said
In 2013 We will grow from 2012 base but not at same rate
In 2012, Folotyn we will double sales in a few years
DEAD WRONG so far
In 2011 n 2012, Zevalin can be $300m drug if we can get admin requirements eased and we are working on it.
DEAD WRONG so far
You can extrapolate the same for their pipeline. Thanks
I think Sec actually started an investigation back in 2013...don't know the status
The fusilev guidance of growth back in fall of 2012 when increasingly there was consolidation of clinics to hospitals, hence more 350b rebates, cost sensitvity of hospitals etc were all known to management.
Despite this back then mgmt was guiding growth. Of course with that contrived guidance of growth mgmt was also able to sell stock 105-b at hyped up stock price of $12.5
Coincidentally after 105-b stock sales in a matter of 2 months they revised fusilev growth forecast downwards of 50%.
Shame shame shameless
Our company needs to buy specialty phase 2 or 3 assets in areas other than just derma or optha
Gilead's acquisition of sovaldi , then a p3 asset, shows how much shareholder value can be added even in big ticket acquisition. Gilead bought it for $11b and now in less than 3 years is earning $20b a year. With the size of the specialty drug market this is replicable.
Let's hope taro looks at the wide array of diseases and not just restrict itself to derma or opth.
I just think they are trying to bait lot of poor investors hyping a failed drug apaz and now sp2012.
Ultimately like in march 2013 where short sellers profited around $80m on "grossly inaccurate"(euphemism) forecast on fusulev....hype of fusilev growth from high base of 2012 kept stock price high at $12.5 ultimately allowing shorts to profit easily around $80m
Also doubling folotyn sales forecast in few years
And getting zevalin to be $300m drug and lobbying to get admin reqt change
So cavejoe how could this be different.
Several hypes here have been to be hypes.
1. Fusilev growth forecast of 2013 of base of 2012
2. Folotyn doubling sales in a few years - given in 2012
3. Zevalin could be $300m drug if we remove some admin reqt and we are working on it.
This was given in 2011 or 2010 I think
Pls remember apaz failed p3 trial in early 2012. until now no trial has been initiated?
How do you know this could not end up as
hype and then failure
Hype gives opp to short sellers to short sell at high price of $8 and then a failure news on say secondary end points, etc will allow short sellers to cover at $5.5
Yes blockbuster data will now be released in couple of months and this will result in a blockbuster increase in stock price....why could they have not waited ?
Don't ever believe in this. The mgt shamelessly changed their growth forecast for fusilev to degrowth of 50 percent in a matter of weeksby putting out a 8k after market....hugely benefiting shorts. The hype helps shorts take their short position
Some things I can conclude based on recent 'blockbuster' announcement
1. Market doesn't believe this management's words
The statements on fusilev, folotyn and zevalin were way off
2. The pattern of hype,heavy shorting and then a shocking, skimpy 8k and short covering is something sec needs to look
Yep. Tartiaboy is a biotech scientist that spends 6 hours on yahoo message board.